SCHEMBL5622296

SCHEMBL5622296

O=C(CCC1CCCc2ccccc21)Nc1ccccc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 5/20 0.54
KDM5A P29375 2/20 0.54
KDM5B Q9UGL1 2/20 0.54
KDM4E B2RXH2 2/20 0.47
PARP1 P09874 1/20 0.44
PARP2 Q9UGN5 1/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 5/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
HCAR2 Q8TDS4 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
HPGD P15428 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9567987 0.90 ALDH1A1 (0.49) KDM4CKDM5AKDM5BKDM4EPARP1
SCHEMBL5623941 0.78 HTR6 (0.51) KDM4CKDM5AKDM5BPARP1PARP2
SCHEMBL9567996 0.78 ALDH1A1 (0.51) KDM4CKDM5AKDM5BKDM4EKMT2A
SCHEMBL9568077 0.76 TRPV1 (0.46) KDM4CKDM5AKDM5BL3MBTL1ALDH1A1
SCHEMBL9567963 0.76 ALDH1A1 (0.44) KDM4CKDM5AKDM5BKMT2AL3MBTL1
SCHEMBL1566782 0.76 SIGMAR1 (0.49) PARP1PARP2ALDH1A1
SCHEMBL9568002 0.74 MEN1 (0.49) KDM4CKDM5AKDM5BKMT2AMEN1
SCHEMBL10585088 0.74 CYP19A1 (0.48) KDM4CKDM5AKDM5BPARP1PARP2
SCHEMBL8993427 0.74 HCAR2 (0.52) KDM4EKMT2AMEN1L3MBTL1ALDH1A1
SCHEMBL9568047 0.74 TRPV1 (0.44) KDM4CKDM5AKDM5BPARP1PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191378-A1 Anthranilic acid derivatives and their use as activators of the hm74a receptor SMITHKLINE BEECHAM CORPORATION (US) 2007-08-16 US disclosed
US-20070191378-A1 Anthranilic acid derivatives and their use as activators of the hm74a receptor SMITHKLINE BEECHAM CORPORATION (US) 2007-08-16 US disclosed
US-20070191378-A1 Anthranilic acid derivatives and their use as activators of the hm74a receptor SMITHKLINE BEECHAM CORPORATION (US) 2007-08-16 US disclosed
EP-1689699-A2 ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR SMITHKLINE BEECHAM CORPORATION (US) 2006-08-16 EP disclosed
WO-2005016867-A2 ANTHRANILIC ACID DERIVATIVES AND THEIR USE AS ACTIVATORS OF THE HM74A RECEPTOR SMITHKLINE BEECHAM CORPORATION (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191378-A1 Anthranilic acid derivatives and their use as activators of the hm74a receptor ANTXR2, HCAR1, GPR88 KDM4C 4812/4885KDM5A 4454/4885KDM5B 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.